Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM), leading to unprecedented responses in this patient population. Idecabtagene vicleucel (ide-cel) has been recently approved for treatment of triple-cla...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanoyan, Dilara Akhoundova, Seipel, Katja, Bacher, Ulrike, Kronig, Marie-Noelle, Porret, Naomi, Wiedemann, Gertrud, Daskalakis, Michael, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105393/
https://www.ncbi.nlm.nih.gov/pubmed/37061680
http://dx.doi.org/10.1186/s12885-023-10824-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105393/
https://www.ncbi.nlm.nih.gov/pubmed/37061680
http://dx.doi.org/10.1186/s12885-023-10824-3

Ejemplares similares